Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chronic Hepatitis C”

1,505 trials

Showing 20 of 1,505 results

Testing effectiveness (Phase 2)Study completedNCT00433069
What this trial is testing

Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone

Who this might be right for
Chronic Hepatitis C
University Hospital, Geneva 5
Not applicableWithdrawnNCT01691235
What this trial is testing

SIMpill Medication Dispensing Device in the Treatment of HCV

Who this might be right for
Chronic Hepatitis C Virus
University of Chicago
Testing effectiveness (Phase 2)Ended earlyNCT02759315
What this trial is testing

Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)

Who this might be right for
Hepatitis C, Chronic
Merck Sharp & Dohme LLC 160
Large-scale testing (Phase 3)Study completedNCT02203149
What this trial is testing

Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)

Who this might be right for
Hepatitis C
Merck Sharp & Dohme LLC 399
Post-approval studies (Phase 4)UnknownNCT00526448
What this trial is testing

Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients

Who this might be right for
Chronic Hepatitis C
Hospital Carlos III, Madrid 384
Testing effectiveness (Phase 2)Study completedNCT01528735
What this trial is testing

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

Who this might be right for
Hepatitis C, Chronic
Boehringer Ingelheim 25
Testing effectiveness (Phase 2)Study completedNCT01717326
What this trial is testing

The Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)

Who this might be right for
Hepatitis C
Merck Sharp & Dohme LLC 573
Testing effectiveness (Phase 2)Study completedNCT01581138
What this trial is testing

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

Who this might be right for
Chronic Hepatitis C Virus
Vertex Pharmaceuticals Incorporated 64
Not applicableStudy completedNCT02581189
What this trial is testing

Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada

Who this might be right for
Chronic Hepatitis C
AbbVie 565
Not applicableUnknownNCT00272389
What this trial is testing

Prediction of Response to Treatment of Patients With Chronic HCV Infection by Genetic Profile

Who this might be right for
Hepatitis C Virus Chronic Infection
Hadassah Medical Organization 150
Testing effectiveness (Phase 2)UnknownNCT00332176
What this trial is testing

Evaluate the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C

Who this might be right for
Chronic Hepatitis C
BioWest Therapeutics Inc 50
Large-scale testing (Phase 3)Study completedNCT02092350
What this trial is testing

Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)

Who this might be right for
Hepatitis C Virus
Merck Sharp & Dohme LLC 237
Early research (Phase 1)Study completedNCT01523990
What this trial is testing

Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients

Who this might be right for
HealthyHepatitis C, Chronic
TaiGen Biotechnology Co., Ltd. 135
Large-scale testing (Phase 3)Study completedNCT02170727
What this trial is testing

A Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1

Who this might be right for
Hepatitis C Virus
Bristol-Myers Squibb 199
Testing effectiveness (Phase 2)Study completedNCT02340962
What this trial is testing

Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection

Who this might be right for
Hepatitis C, Chronic
TaiGen Biotechnology Co., Ltd. 25
Testing effectiveness (Phase 2)Study completedNCT01710501
What this trial is testing

Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)

Who this might be right for
Chronic Hepatitis C (CHC)
Merck Sharp & Dohme LLC 87
Post-approval studies (Phase 4)Study completedNCT00107653
What this trial is testing

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

Who this might be right for
Hepatitis C, Chronic
Hoffmann-La Roche 569
Testing effectiveness (Phase 2)Study completedNCT00991289
What this trial is testing

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

Who this might be right for
HIV InfectionHepatitis C Infection
National Institute of Allergy and Infectious Diseases (NIAID) 68
Post-approval studies (Phase 4)WithdrawnNCT04614142
What this trial is testing

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

Who this might be right for
End Stage Renal DiseaseChronic Hepatitis c
Massachusetts General Hospital
Large-scale testing (Phase 3)Study completedNCT01725529
What this trial is testing

An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients

Who this might be right for
Hepatitis C, Chronic
Janssen R&D Ireland 457
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation